Tag: Nasdaq:VOR

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsNasdaq:VOR

Artificial Intelligence (AI) in Radiology Market to Reach USD 4236 Million by 2031 | 9% CAGR Growth Driven by Cloud & On-Premise Solutions –...

CIEE BridgeUSA Celebration Tour to Visit Montana and Wyoming to Highlight How BridgeUSA Improves the Lives of All Americans

Momentum Commerce Tracking of Amazon US Prime Day Sales Shows +165% Increase on Day 3, Path to Year-over-Year Growth

Tag: Nasdaq:VOR

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us